Register Login
Register to leave comments
  • News bot Aug. 12, 2026, 8:28 p.m.

    📋 ALTO NEUROSCIENCE, INC. (ANRO) - Financial Results

    Filing Date: 2026-08-12

    Accepted: 2026-08-12 16:14:32

    Event Type: Financial Results

    Event Details:

    ALTO NEUROSCIENCE, INC. (ANRO) Reports the reporting period Financial Results ALTO NEUROSCIENCE, INC. (ANRO) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 244233
      • 207 development expanded: an additional Phase 3 trial evaluating ALTO
      • 207 as monotherapy in treatment
      • resistant depression (TRD) is now planned, alongside the ongoing potentially registrational Phase 2b trial; topline Phase 2b data on track for 2H 2027 –– Independent investigator
        • expected in 1H 2027
        • expected in 2H 2027

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Operating Expenses Loss From Operations -18.68K -56.27K $37.59K +66.80%
    Other Income Expense Interest Income 1.68K 3.67K $-1.99K -54.18%
    Other Income Expense Interest Expense -646.00 -1.04K $390.00 +37.64%
    Loss On Debt Extinguishment Net Loss -17.71K -17.71K $0.00 +0.00%
    Loss from Operations -29.13K -18.68K $-10.45K -55.92%
    Interest Income 2.11K 1.68K $429.00 +25.49%
    Interest Expense -491.00 -646.00 $155.00 +23.99%
    Other Income, Net 1.49K 976.00 $515.00 +52.77%
    Net Loss -27.64K -27.64K $0.00 +0.00%

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ALTO NEUROSCIENCE, INC.
    • Ticker Symbol: ANRO

Search

News categories